AACR 2018: Updated OS data for olaparib in gBRCA-Mutated HER2 negative metastatic breast cancer
Data from the Phase III OlympiAD trial, showing the final overall survival (OS) results for…
Data from the Phase III OlympiAD trial, showing the final overall survival (OS) results for…